Clinical Risk Factors for Central Line-Associated Venous Thrombosis in Children by Samir H. Shah et al.
ORIGINAL RESEARCH
published: 05 May 2015
doi: 10.3389/fped.2015.00035
Edited by:
Jan Hau Lee,
KK Women’s and Children’s Hospital,
Singapore
Reviewed by:
Christoph P. Hornik,
Duke University, USA
Jacqueline Ong,
National University Healthcare
System, Singapore
Kozue Shimabukuro,
Loma Linda University Children’s
Hospital, USA
*Correspondence:
Samir H. Shah,
Le Bonheur Children’s Hospital,
Room 346R, 50 N. Dunlap Street,
Memphis, TN 38103, USA
sshah7@uthsc.edu
Specialty section:
This article was submitted to Pediatric
Critical Care, a section of the journal
Frontiers in Pediatrics
Received: 08 December 2014
Accepted: 08 April 2015
Published: 05 May 2015
Citation:
Shah SH, West AN, Sepanski RJ,
Hannah D, May WN and Anand KJS
(2015) Clinical risk factors for central
line-associated venous thrombosis
in children.
Front. Pediatr. 3:35.
doi: 10.3389/fped.2015.00035
Clinical risk factors for central
line-associated venous thrombosis
in children
Samir H. Shah 1*, Alina Nico West 1,2, Robert J. Sepanski 3, Debbie Hannah 4,
William N. May 5 and Kanwaljeet J. S. Anand 1
1 Department of Pediatrics, University of Tennessee Health Science Center, Le Bonheur Children’s Hospital Memphis,
Memphis, TN, USA, 2 Children’s Foundation Research Institute, Le Bonheur Children’s Hospital, Memphis, TN, USA,
3 Department of Performance Improvement and Patient Safety, Children’s Hospital of The King’s Daughters, Norfolk,
VA, USA, 4 Department of Quality Improvement, Le Bonheur Children’s Hospital, Memphis, TN, USA, 5 Le Bonheur Children’s
Hospital, Memphis, TN, USA
Background: Identifying risk factors related to central venous line (CVL) placement could
potentially minimize central line-associated venous thrombosis (CLAVT). We sought to
identify the clinical factors associated with CLAVT in children.
Methods: Over a 3-year period, 3733 CVLs were placed at a tertiary-care children’s
hospital. Data were extracted from the electronic medical records of patients with
clinical signs and symptoms of venous thromboembolism, diagnosed using Doppler
ultrasonography and/or echocardiography. Statistical analyses examined differences in
CLAVT occurrence between groups based on patient and CVL characteristics (type,
brand, placement site, and hospital unit).
Results: Femoral CVL placement was associated with greater risk for developing CLAVT
(OR 11.1, 95% CI 3.9–31.6, p<0.0001). CVLs placed in the NICU were also associated
with increased CLAVT occurrence (OR 5.3, 95% CI 2.1–13.2, p=0.0003). CVL brand
was also significantly associated with risk of CLAVT events.
Conclusion: Retrospective analyses identified femoral CVL placement and catheter type
as independent risk factors for CLAVT, suggesting increased risks due to mechanical
reasons. Placement of CVLs in the NICU also led to an increased risk of CLAVT, suggest-
ing that small infants are at increased risk of thrombotic events. Alternative strategies for
CVL placement, thromboprophylaxis, and earlier diagnosis may be important for reducing
CLAVT events.
Keywords: pediatric critical illness, central venous line thrombosis, pediatric thrombosis risk factors, clinical
outcomes of pediatric thrombosis, pediatric thrombosis morbidity
Introduction
The incidence of venous thromboembolism (VTE) is increasing in the hospitalized pediatric popula-
tion (1–4). This is surprising due to the previously described rarity of this potentially fatal condition
(5). Although variable across institutions, an overall VTE incidence of 188/100,000 hospitalized
pediatric patients was found in the retrospective KID database (3, 6). The overall incidence of
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VTE may have increased recently, since there are no current
established guidelines for pediatric thromboprophylaxis (4, 7, 8).
A multifactorial process leads to VTE development in
hospitalized children, possibly related to their age and
race, primary diagnoses, congenital and genetic factors, and
mechanical factors (3, 4, 9). Retrospective and prospective studies
have identified higher risks for VTE in children below 1 year
of age, adolescents, children with specific renal, hematologic,
infectious, traumatic, and oncologic diagnoses, and those
exposed to mechanical factors (1, 4, 7, 10, 11). Beck et al. found
sonographic evidence of venous thrombosis in 18.3% of children
requiring a central venous line (CVL) (11).
Central venous line insertion is associated with multiple com-
plications including central line-associated bloodstream infec-
tions (CLABSI) and thrombosis (12, 13). AlthoughCLABSI is well
characterized in pediatric and adult hospitalized patients, VTE
development is less studied in the pediatric population (1, 14). To
date, there are no published guidelines for the diagnosis of central
line-associated venous thrombosis (CLAVT) in children (14). The
diagnosis of CLAVT has depended upon clinical signs and symp-
toms, the use of Wells’ criteria, along with imaging studies such as
Doppler ultrasound and traditional venography (1, 4).
We conducted a retrospective cohort study to identify risk fac-
tors associated with CLAVT incidence in a tertiary-care children’s
hospital. We hypothesized that CLAVT identified via ultrasound
imaging would be increased in children <1 year of age and those
with femoral CVL placement.
Materials and Methods
Data Collection
With Institutional Review Board approval, data were collected on
3733 CVLs placed within a 3-year period (2010–2012). The num-
ber of charts reviewed did include placement of multiple central
lines in the same patient. “Symptomatic” CLAVT was defined as
thrombosis associated with a blocked or leaking CVL, progres-
sive distal limb edema, or clinical signs of pulmonary embolism
(chest pain, shortness of breath, tachycardia, tachypnea, hypoxia,
hemoptysis). Standard nursing assessment of either the presence
or absence of venous thrombosis was done every 12 h and CLAVT
was characterized by redness, edema, and presence/absence of
a distal pulse. CLAVT was confirmed via either Doppler ultra-
sonography (with increased echogenicity at the site or presence
of a filling defect) or with presence of a thrombus on echocardio-
graphy. Patients with venous thrombosis either present at hospital
admission or unrelated to CVL placement were excluded. The
following variables were included hospital location of catheter
placement, catheter type, CVL placement site, number of attempts
to place CVL, and use of ultrasonography for vascular access.
Statistical Analyses
In order to adjust for bias associated with low occurrence of
CLAVT in many of the subcategories being examined, the Firth
method of multiple logistic regression based on a penalized
maximum likelihood function was used to analyze associations
betweenCLAVT and line type (Arrow™, Cook™, Broviac™, PICC,
and All Other), CLAVT and unit of insertion (OR, PICU, NICU,
All Other), and CLAVT and anatomical insertion site (Femoral,
Jugular, Subclavian, Upper Extremity, and All Other). “All other”
subcategories represented groupings of all but the categories that
were most common in each dataset.
Results
The numbers of CLAVT events are listed in Table 1. The associ-
ation of total number of central lines placed with the number of
CLAVTevents shows a slight decline of events in 2011 and 2012, in
comparison to data shown for 2010. The number of CLAVTevents
per total annual catheter number increased in the PICU compared
to other hospital locations at the end of the 3-year period (Table 2).
Although in 2010, theNICUhad the highest percentage ofCLAVT
events. Additionally, CVL placement in the NICU had a higher
odds ratio than other units (OR 5.3, 95% CI 2.1–13.2, p= 0.0003;
Table 3).
Risk factor assessment (Table 3) showed that femoral vein
placement contributed significantly to CLAVT (OR 11.1, 95% CI
3.9–31.6, p< 0.0001), in comparison to upper extremity lines.
Broviac™ and Cook™ catheters were also more commonly asso-
ciated with CLAVT (Table 3).
Discussion
Central line-associated venous thrombosis is a significant iatro-
genic complication of critical illness in our tertiary-care facility.
Significant risk factors at our facility include anatomical site,
hospital location of CVL placement, and types of lines placed.
Variability exists in the diagnosis of CLAVT and its incidence
based on clinical risk factors (6). Our finding that small children,
specifically NICU patients, have the highest number of CLAVT
events is consistent with previous studies of children with central
venous catheters (1, 3, 4, 7, 8, 11).
Central venous line characteristics, including type, brand, and
anatomic site of insertion and their relationship to number of
CLAVT events were evaluated in this study. Our data support
the well-established postulate that femoral CVLs predispose pedi-
atric patients to CLAVT, especially in hospitalized children below
1 year of age (4, 15). Higgerson et al. found that femoral DVTs
TABLE 1 | Number of CLAVT Events in a single tertiary pediatric hospital.
2010 2011 2012
Total number of central lines 946 1439 1348
CLAVT 20 21 21
Patients with 2 CLAVT events 2 0 N/Aa
aData from 2012 was de-identified.
TABLE 2 | Percentage of CLAVT events per hospital unita.
Year PICU CVICU NICU Hospital-wide
2010 2.98 0 7.41 2.11
2011 3.53 3.85 1.40 1.46
2012 4.03 2.04 0.79 1.56
aPICU, pediatric intensive care unit; CVICU, cardiovascular intensive care unit; NICU,
neonatal intensive care unit.
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TABLE 3 |Multiple logistic regression analysis of 3733 central venous linesa.
Multiple logistic regression resultsa (dependent variable = CLAVT
occurrence)
Independent
variable
Subcategory CLAVT lines/
all lines in
subcategory
Adjusted
odds ratio
(95% CI)
p
CVL line type PICC (reference) 5/1227 1.0 (–) –
Arrow™ 11/541 4.2 (0.9–18.8) 0.06
Broviac™ 6/325 8.9 (1.9–41.9) 0.006
Cook™ 33/742 4.2 (1.0–17.2) 0.05
All other line types 7/898 3.8 (0.8–17.6) 0.09
Unit (CVL
placement)
OR (reference) 13/1279 1.0 (–) –
NICU 11/377 5.3 (2.1–13.2) 0.0003
PICU 27/757 1.7 (0.8–3.8) 0.17
All other units 11/1320 1.0 (0.4–2.2) 0.95
CVL insertion
site
Subclavian
(reference)
5/931 1.0 (–) –
Femoral 37/473 11.1 (3.9–31.6) <0.0001
Jugular 7/502 2.4 (0.7–7.7) 0.15
Upper extremity 3/832 1.7 (0.3–11.2) 0.58
All other sites 10/995 1.9 (0.7–5.5) 0.23
aUsing Firth’s method of penalized maximum likelihood.
Reference subcategories were chosen as ones having the lowest frequency of CLAVT
occurrence from among those having the highest frequency of CVL’s. Subcategories
showing an association with CLAVT that differs significantly from the reference subcat-
egory are highlighted in bold.
occur in mechanically ventilated PICU patients, whether or not
they were CVL-related (7). We found that the highest number of
CLAVTs occurred in PICU patients, with a slight decrease in the
number of line events in 2012, likely due to a Hawthorne effect.
Nonetheless, our findings are congruent with these previously
published data, both suggesting that CLAVT is a growing prob-
lem in the PICU population. Other CVL characteristics – CVL
type and brand – did not have a significant impact on CLAVT
development in a study by Male et al. (16). Broviac™ and Cook™
catheters were significantly associated with CLAVT risk in our
study; however, a larger, prospective study is needed to assess this
risk factor more precisely.
Overall, the incidence of CLAVT minimally increased over a
3-year period. Increased awareness of the study itself could have
lead to increased diagnosis in 2011 and 2012. Also, in our patients
with symptomatic CLAVT, the probability of screening could
potentially be higher (17).
There are several limitations of this retrospective study. CLAVT
is associated with increasedmortality and increased length of stay,
especially in the PICU, but we did not have adequate sample size
to examine these outcomes in our study (1, 4, 7, 18). Considering
the association of CLAVT with increased mortality, it would have
been prudent to assess levels of critical illness. Only information
on symptomatic VTEs, based on clinical signs and symptoms,
was captured in this study and confirmed by the use of Doppler
ultrasonography or echocardiography. Geerts et al. assert that the
ratio of asymptomatic to symptomatic DVT ranges from 5:1 to
10:1 and that asymptomatic DVT evolves to symptomatic VTE
(17). Asymptomatic CLAVTs were probably undetected in our
patients and therefore, we will evaluate CLAVT prospectively
in order to gather more data including diagnostic methods and
primary diagnoses. CLABSI association was not addressed in this
study, as our dataset was limited. Lastly, the use of thrombopro-
phylaxis was not evaluated during this study. Guidelines for use of
thromboprophylaxis in pediatric patients have been based upon
adult guidelines (19). It is essential to evaluate thromboprophy-
laxis prospectively, in order to establish which anti-thrombolytic
therapies are most effective in pediatric patients (4).
Despite the limitations of this study, we found that ICU patients
with femoral CVL placement had the highest incidence of CLAVT
in our facility. Based on increased awareness, it would be pos-
sible to reach an earlier diagnosis and evaluation interventions
to decrease CLAVT rates. Prospective, multicenter studies are
warranted to enhance earlier diagnostic strategies and to deter-
mine the most effective thromboprophylaxis and antithrombotic
interventions required for PICU patients.
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